Zydus Lifesciences Limited has announced the successful completion of its cash tender offer for all outstanding shares of common stock of Assertio Holdings, Inc. through its wholly-owned subsidiary, Zara Merger Sub Inc. The acquisition was completed at a purchase price of USD 23.50 per share of Assertio common stock, without interest and less deduction for any required withholding taxes.
As of the tender offer expiration on June 15, 2026, approximately 4,286,488 shares were validly tendered and not withdrawn, representing about 66.32% of the total issued and outstanding shares of Assertio. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Zydus Lifesciences expects to promptly pay for these shares. The cash offer was made through Zara Merger Sub Inc. the purchasing subsidiary.
Zydus Lifesciences intends to complete the acquisition through a merger of the Purchaser with and into Assertio, with Assertio continuing as the surviving corporation. Shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the offer price of USD 23.50 per common share, without interest and less deduction for any required withholding taxes.
Following the merger, Assertio will become a wholly-owned subsidiary of Zydus Lifesciences Limited. The common stock of Assertio will no longer be listed or traded on the Nasdaq Global Market after the completion of the transaction.
Zydus Lifesciences Limited is an innovative global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in research and development.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.